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        Semaphorins are a large family of either mem-
brane-bound or secreted proteins that were 
originally described in the nervous system, 
where they are involved in the establishment of 
a correct neuronal network (  1, 2  ). These lig-
ands exert their activities by binding to high 
affi   nity receptors known as plexins, a family of 
transmembrane molecules that share structural 
homology with semaphorins themselves (  3  ). 
An increasing amount of data show that these 
two protein families also exert their action out-
side the nervous system, as they play a critical 
role in cardiac and skeletal development (  4, 5  ), 
immune response (  6, 7  ), epithelial morphogen-
esis (  8  ), and tumor growth and metastatization 
(  9, 10  ). Moreover, studies suggest that these 
molecules are important players during angio-
genesis, as they regulate blood vessel growth 
and endothelial cell (EC) homing during vessel 
development (  11  ). Although secreted class III 
semaphorins inhibit EC migration and in vitro 
vessel formation (  12  ), class IV semaphorins posi-
tively regulate angiogenesis (  13, 14  ). Angiogen-
esis is a complex, multistep process in which 
ECs of preexisting blood vessels, challenged by 
appropriate biochemical and physical cues, dy-
namically remodel their cell-to-cell and cell-to-
matrix adhesions and reorganize themselves into 
a mature, hierarchically organized system of hol-
low endothelial tubes that is eventually stabilized 
by interaction with pericytes. 
  We and others have identifi  ed semaphorin 
4D (Sema4D), also known as CD100, as a po-
tent proangiogenic molecule (  13  –  17  ). Sema4D, 
originally discovered in the immune system, 
where it regulates B cell aggregation and survival 
and T cell activation (  18, 19  ), can be found ei-
ther as a 150-kD membrane-bound form or as a 
120-kD soluble molecule; the latter is originated 
as a consequence of a proteolytic cleavage (  17, 
20, 21  ). Sema4D acts by binding to its high af-
fi  nity receptor, plexin B1 (  3  ), to an intermediate 
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    Increased evidence suggests that cancer-associated infl  ammation supports tumor growth 
and progression. We have previously shown that semaphorin 4D (Sema4D), a ligand pro-
duced by different cell types, is a proangiogenic molecule that acts by binding to its recep-
tor, plexin B1, expressed on endothelial cells (Conrotto, P., D. Valdembri, S. Corso, G. Serini, 
L. Tamagnone, P.M. Comoglio, F. Bussolino, and S. Giordano. 2005.   Blood  . 105:4321  –  4329). 
The present work highlights the role of Sema4D produced by the tumor microenvironment 
on neoplastic angiogenesis. We show that in an environment lacking Sema4D, the ability of 
cancer cells to generate tumor masses and metastases is severely impaired. This condition 
can be explained by a defective vascularization inside the tumor. We demonstrate that 
tumor-associated macrophages (TAMs) are the main cells producing Sema4D within the 
tumor stroma and that their ability to produce Sema4D is critical for tumor angiogenesis 
and vessel maturation. This study helps to explain the protumoral role of infl  ammatory cells 
of the tumor stroma and leads to the identifi  cation of an angiogenic molecule that might 
be a novel therapeutic target. 1674 STROMAL S  EMA  4D CONTRIBUTES TO TUMOR ANGIOGENESIS AND METASTASIS   | Sierra et al. 
  Fig. 1 (B  –  D)  , we observed a reduced incidence of metastases 
in KO versus WT mice (P   <   0.0001). Collectively, these re-
sults indicate that the presence of Sema4D in the tumor micro-
environment contributes to tumor growth and metastasis. 
  Maturation of tumor vessels is impaired in Sema4D KO mice 
  We wondered if the decreased tumorigenic ability observed in 
Sema4D KO mice could be caused by altered vasculogenesis. 
Thus, we stained slices of tumors of comparable size, grown 
either in WT or KO mice, with anti-CD31 antibody (a marker 
of ECs;   Fig. 2 A  ).   Although the total number of vessels was 
similar in the two types of animals (  Fig. 2 B  , top), the total 
vessel area and mean vessel size were signifi  cantly smaller in 
tumors grown in Sema4D KO mice (P   <   0.0001;   Fig. 2 B  , 
middle and bottom). 
  Interactions between ECs and pericytes in the vessel walls 
have been recently identifi  ed as central processes in the regula-
tion of vascular formation, stabilization, remodeling, and func-
tion (  28  ). Failure of the interactions between these cell types 
has been described in some human pathologies, including tu-
mor angiogenesis (  29  ). Because pericytes are recruited by stro-
mal-derived cytokines (  30  ), we decided to verify if they were 
normally localized along the altered vessels of tumors grown in 
Sema4D KO mice. We thus stained tumor slices with anti-NG2, 
an antibody that identifi  es pericytes. As shown in   Fig. 2 C  , 
vessels of tumors originated in KO mice very rarely showed a 
normal interaction between ECs and pericytes. Most of them, 
in fact, were negative for the presence of pericytes, which were 
instead normally present in tumors that originated in control 
mice. Collectively, these observations suggest that Sema4D 
plays a role in tumor angiogenesis, where it contributes to the 
maturation of tumor vessels by acting on ECs and favoring the 
recruitment of pericytes. 
  Bone marrow  –  derived cells produce Sema4D that contributes 
to tumor growth and vessel organization 
  The results of the previous experiments suggest that cells of the 
tumor microenvironment produce the Sema4D that is re-
quired to promote tumor angiogenesis. To identify these cells, 
we performed immunofl  uorescent stainings on tumor slices. 
As shown in   Fig. 3 A  , most of the cells positive for Sema4D 
were also stained by an anti-CD45 mAb, suggesting that they 
belong to the leukocyte lineage (P   <   0.0001).   
  To prove that bone marrow  –  derived cells are indeed the 
major producers of the semaphorin, we performed bone mar-
row transplantation experiments. We injected WT male  –  de-
rived bone marrow cells into female KO animals. PCR analyses 
performed 2 wk later (evaluating the presence of the Y chro-
mosome in peripheral leukocytes) showed that the mice were 
chimeric, with     70% of their leukocytes derived from WT 
marrow (  Fig. 3 B  , bottom). We thus injected these chimeric 
mice with tumor cells and evaluated tumor growth. As shown 
in   Fig. 3 B  , tumors grown in chimeric KO mice were bigger 
than those grown in KO animals. As expected, we found many 
CD45  +   cells expressing Sema4D in tumors grown in KO mice 
transplanted with WT bone marrow (unpublished data). 
affi   nity receptor, plexin B2 (both of which are widely ex-
pressed) (  22  ), or to a low affi   nity receptor, CD72, which is 
mainly expressed by cells of the hematopoietic lineage (  23  ). 
Sema4D and plexin B1/B2 share structural homology with 
the tyrosine kinase receptors c-Met and Ron (  24, 25  ). We 
have previously shown that activation of plexin B1 through 
Sema4D binding transactivates c-Met and promotes the inva-
sive ability of tumor cells (  8  ). Moreover, we have also demon-
strated that Sema4D, upon binding plexin B1 and activating 
c-Met, promotes angiogenesis both in vitro and in vivo (  13  ). 
  Reports have recently pointed out the close correlation be-
tween infl  ammatory infi  ltration of the tumor stroma and a high 
vascular grade (  26, 27  ). Because Sema4D is produced by in-
fl  ammatory cells present in the tumor microenvironment (  7  ), 
we wanted to assess whether stroma-derived Sema4D could 
infl  uence the tumorigenic ability of cells as well as their capac-
ity to originate metastasis. In this paper, we show that in an 
environment lacking Sema4D, the ability of breast cancer cells 
to originate tumor masses and metastases is severely impaired. 
This impairment is paralleled by an altered vascularization in-
side the tumor. We also provide evidence that the main cells 
producing the semaphorin in the tumor stroma are the tumor-
associated macrophages (TAMs), and that TAM-derived 
Sema4D is critical for tumor angiogenesis and for the matura-
tion of blood vessels. This work thus highlights a novel func-
tion of cells involved in the infl  ammatory response of tumors 
and identifi  es Sema4D as a new player in the complex interac-
tion between tumor cells and the tumor microenvironment. 
    RESULTS   
  Tumor growth and metastatic ability of breast cancer cells 
is impaired in Sema4D KO mice 
  Previous works have shown that Sema4D is endowed with 
angiogenic properties, both in vitro and in vivo (  13  –  15  ). 
However, Sema4D is dispensable for the formation of ves-
sels during embryogenesis, as Sema4D KO mice are viable 
(  19  ). To investigate if Sema4D might play a role in patho-
logical vasculogenesis, such as that taking place in tumors, 
we grafted syngeneic tumor cells (TSA, breast cancer) both in 
WT and in Sema4D KO (KO) mice. As shown in   Fig. 1 A  , 
tumor growth was signifi  cantly impaired in mice lacking 
Sema4D in comparison to WT mice (an almost sixfold re-
duction at the end of the experiment; P   <   0.0001).   Similar 
experiments performed with three other breast cancer cell 
lines (66cl4, 4T1, and 168FARN) gave similar results, as the 
grafted cells originated smaller tumors in KO mice in com-
parison to the WT animals (Fig. S1, available at http://www
.jem.org/cgi/content/full/jem.20072602/DC1). 
  We have previously demonstrated that Sema4D acts not 
only on ECs but also on tumor cells and that it stimulates 
their invasive ability (  8  ). After proving that TSA cells do 
express plexin B1, the high affi   nity receptor for Sema4D, 
and display enhanced in vitro motility and invasiveness in 
response to the semaphorin (Fig. S2, available at http://www
.jem.org/cgi/content/full/jem.20072602/DC1), we evaluated 
their metastatic ability in KO and WT mice. As shown in JEM VOL. 205, July 7, 2008 
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vascular grade only in tumors grown in mice having WT bone 
marrows (either endogenous or transplanted;   Fig. 3, D and E  ). 
Collectively, these experiments suggest that in the tumor 
microenvironment, bone marrow  –  derived cells produce the 
Sema4D that contributes to vessel maturation and, eventually, 
tumor growth. 
  Sema4D produced by platelets does not contribute 
to tumor growth 
  It has been recently reported that activated platelets express 
Sema4D and that the surface expression of the semaphorin 
increases during platelet activation, followed by the gradual 
  We also performed the reverse experiment by analyzing 
tumor growth in lethally irradiated (900 cGy) WT female mice 
transplanted with bone marrow cells derived from KO male 
mice (  Fig. 3 C  , bottom). As shown in   Fig. 3 C  , tumors grown 
in WT mice transplanted with KO-derived bone marrow cells 
were smaller compared with those grown in WT animals trans-
planted with WT bone marrow. When we counted CD45  +   
cells inside tumors, we observed a slight decrease of bone mar-
row  –  derived cells in mice transplanted with KO bone mar-
row versus those transplanted with WT bone marrow (mean 
CD45  +   cells/fi  eld = 48.5   ±   8.7 and 38.7   ±   7.8, respectively). 
When we analyzed tumor vascularization, we found a high 
    Figure 1.         Tumor growth and metastatic ability of breast cancer cells is impaired in Sema4D KO mice.   (A) TSA breast cancer cells were subcutane-
ously injected in WT and Sema4D KO mice. Tumor volume was evaluated at the indicated days. As shown, tumor burden was dramatically less in Sema4D KO 
versus WT mice. Bars indicate mean tumor volume   ±   SEM. *, P   <   0.0001 (  n   = 10 mice per group). (B and C) Macro- and micrometastases present in the lungs 
of mice bearing tumors of comparable size were evaluated as indicated in Materials and methods and scored. Error bars indicate mean   ±   SD. *, P   <   0.0001 
(  n   = 10 lungs). (D) Representative pictures of lungs and lung slices for WT and Sema4D KO mice. As shown, the number of metastases was signifi  cantly 
lower in Sema4D KO mice. Statistical differences between groups were determined by using the two-tailed Student  ’  s   t   test. Bars: (whole mount) 0.5 cm; 
(micrograph) 0.2 mm.     1676 STROMAL S  EMA  4D CONTRIBUTES TO TUMOR ANGIOGENESIS AND METASTASIS   | Sierra et al. 
shedding of its extracellular domain (  21  ). It is widely ac-
cepted that blood clotting can contribute to tumor growth 
and dissemination by creating a fi  brin clot surrounding tu-
mor cells that can protect them from apoptosis (  31  ). We 
wondered if platelets could be the bone marrow  –  derived 
    Figure 2.         Tumor vascularization is altered in Sema4D KO mice.   (A and B) Evaluation of tumor vascularization. Blood vessel staining of tumor histo-
logical sections was performed with an anti-CD31 antibody. The number and area of vessels were evaluated by fl  uorescence microscopy. As shown, al-
though the number of vessels is not signifi  cantly different, vessel area and size are signifi  cantly reduced in Sema4D KO mice. Error bars indicate mean   ±   
SD. *, P   <   0.0001 (  n   = 8 mice per group, with 10 fi  elds per animal). Bars, 100   μ  m. (C) To evaluate the presence of vessel-associated pericytes, tumor sec-
tions were costained with the pericyte-specifi  c antibodies NG2 (red) and CD31 (green). Analysis was performed on one slice per mouse (  n   = 8 mice per 
group). As shown, vessels of tumors that originated in KO mice very rarely showed a normal interaction between ECs and pericytes, and in most cases 
they stained negative for the presence of pericytes (right), which were instead normally present in tumors originated in control mice (left). Statistical 
differences between groups were determined by using the two-tailed Student  ’  s   t   test. v.f., visual fi  eld. Bars, 50   μ  m.     
elements contributing the Sema4D responsible for tumor 
promotion. We thus grafted TSA cells in WT and in KO mice 
chronically treated with clopidogrel, a widely used inhibitor 
of platelet activation (  32  ). Platelet inactivation was proven by 
analyzing the expression of CD62P on platelets obtained from JEM VOL. 205, July 7, 2008 
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treated and untreated animals. Mice treated with clopidogrel 
failed to expose CD62P on their membrane (unpublished data). 
As shown in Fig. S3 (available at http://www.jem.org/cgi/
content/full/jem.20072602/DC1), we did not observe sig-
nifi  cant changes in the growth of tumor xenografts in mice 
    Figure 3. Bone marrow  –  derived cells produce Sema4D that contributes to tumor growth and vessel organization.   (A)  CD45 +   cells express Sema4D. 
To evaluate whether CD45  +   cells express Sema4D, tumor slices were costained with CD45 and Sema4D antibodies. Double-positive cells were then counted on 
10 slices per group (one slice per tumor). (right) As shown,     85% of the leukocytes express Sema4D. Error bars indicate mean   ±   SD. *, P   <   0.0001. Bar, 50   μ  m. 
(B) WT-derived bone marrow cells rescue tumor burden. (top) The mean volume   ±   SEM of grafted tumors in WT mice, Sema4D KO mice, and Sema4D KO mice 
transplanted with WT-derived bone marrow (BMT;   n   = 6 tumors per group). As shown, tumors grown in transplanted KO mice were bigger than those grown 
in nontransplanted KO mice. (bottom) PCR amplifi  cation of the ZFY1 gene on the Y chromosome from DNA derived from peripheral leukocytes. As shown, 
transplanted mice were chimeric, displaying     70% of leukocytes derived from the donors (for experimental details, see Materials and methods). W1 and W2 
indicate representative transplanted mice, and female and male DNA are shown. (C) Sema4D KO bone marrow transplantation leads to decreased tumor bur-
den in WT females. Lethally irradiated (900 cGy) WT females were transplanted with bone marrow cells derived from KO or WT male mice (  n   = 8 tumors per 
group). Bars indicate mean volume   ±   SEM. As in B, engraftment was confi  rmed by PCR analysis (bottom). K, Sema4D KO mice. (D and E) Tumor vessels re-
semble the phenotype of the original bone marrow donor when stained by CD31 antibody (compare with   Fig. 2  ). D shows vessels, stained with CD31 antibod-
ies, in a tumor grown in Sema4D KO mice transplanted with WT bone marrow. E shows slices derived from tumors grown in WT animals transplanted with WT 
(top) or KO (bottom) bone marrow. Statistical differences between groups were determined by using the two-tailed Student  ’  s   t   test. Bars, 100   μ  m.    
in which platelet activation was inhibited. Similar results were 
obtained when platelet activation was inhibited by aspirin 
(unpublished data). These experiments indicate that platelet-
derived Sema4D is not critical to elicit the tumorigenic ability 
of breast cancer cells. 1678 STROMAL S  EMA  4D CONTRIBUTES TO TUMOR ANGIOGENESIS AND METASTASIS   | Sierra et al. 
rounding tissues and metastasize (  34  –  36  ). Immunofl  uores-
cence revealed that most of the leukocytes in the tumor stroma 
were indeed macrophages (  Fig. 4 A  ), and that they expressed 
Sema4D (  Fig. 4, B and C  ).   
  To evaluate if the expression of Sema4D is linked to 
monocyte/macrophage diff  erentiation or to macrophage ac-
tivation, we performed some in vivo experiments. We in-
duced experimental peritonitis in mice by injection of CFA; 
3 d later, we collected peritoneal macrophages and compared 
the expression of Sema4D on these cells versus resident peri-
toneal macrophages obtained from control mice. As shown 
  Macrophages are the main source of Sema4D 
in the tumor microenvironment 
  As shown in   Fig. 3 B  , we have observed that transplantation 
of bone marrow from WT to KO animals could rescue the 
impairment of tumor growth. In recent years, compelling 
evidence supports the idea that TAMs, which account for the 
majority of the infi  ltrating infl  ammatory cells into the tumor 
mass and exhibit a phenotype distinct from any other activated 
monocytes, play an integral role during tumor progression (  33  ). 
These cells, in fact, produce cytokines that aid the proliferation 
and survival of tumor cells, as well as their ability to invade sur-
    Figure 4.         TAMs produce Sema4D that acts on ECs.   (A and B) Immunofl  uorescence analysis of tumors grown in WT or Sema4D KO animals. In A, stain-
ing with CD45 and F4/80 (specifi  c for macrophages) reveals that most of the leukocytes in the tumor stroma are macrophages (    90%; not depicted). In B, 
staining with F4/80 and Sema4D antibody reveals that TAMs express Sema4D. Bars, 50   μ  m. (C) Western blot analysis of total cell lysates of TAMs derived from 
WT or Sema4D KO mice. The blot was probed with anti-Sema4D antibodies and, as a loading control, with anti  –      -actin. (D) PCR analysis performed on RNAs 
obtained from peritoneal macrophages of control mice (left) or of mice injected i.p. with CFA. As shown, only activated macrophage express Sema4D. (E) Tran-
swell motility assays. The ability of supernatants of cultures of TAMs, purifi  ed from tumors grown either in WT or KO mice, to promote EC (HUVEC) migration 
was evaluated. Supernatants of WT TAMs effi  ciently promoted EC migration, whereas supernatants of KO TAMs were signifi  cantly less effective. Moreover, the 
chemoattractive activity of the WT supernatant was signifi  cantly decreased in the presence of Sema4D or plexin B1 blocking antibodies, and of the c-Met 
inhibitor PHA-665752. Chemoattractive positive controls included Sema4D (4D) and HGF, whereas anti-VSV was used as a control antibody. Bars represent 
the mean   ±   SD (experiments were performed twice in triplicate). Statistical differences between groups were determined by using the two-tailed Student  ’  s   t   
test. *, P = 0.0003; **, P = 0.0002; ***, P = 0.0013; and #, P = 0.0001.    JEM VOL. 205, July 7, 2008 
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in   Fig. 4 D  , although Sema4D was not expressed in resting 
macrophages, it was up-regulated in activated macrophages. 
Similar results were also obtained from the analysis of human 
cells; in fact, although monocytes did not express Sema4D, 
activated macrophages did (Fig. S4, available at http://www
.jem.org/cgi/content/full/jem.20072602/DC1). Moreover, 
we found that, in vitro  ,   Sema4D expression was not induced 
by diff  erentiating stimuli (M-CSF, PMA, IL-10, or TGF-    ), 
whereas it was induced by activating molecules (such as LPS; 
Fig. S4). All of these data suggest that the expression of 
Sema4D is not strictly liked to monocyte/macrophage diff  er-
entiation, and that this molecule is expressed on diff  erent 
types of activated macrophages. 
  We then analyzed whether macrophages of KO mice be-
haved normally in term of response to activating stimuli and of 
cytokine production. As shown in Fig. S5 (available at http://
www.jem.org/cgi/content/full/jem.20072602/DC1), mac-
rophages from Sema4D KO mice were indeed able to respond 
to LPS by increasing the production of cytokines such as 
TNF-    . Moreover, we did not observe signifi  cant diff  erences 
in cytokine production between WT- and KO-derived TAMs 
(Fig. S5), or in their ability to diff  erentiate in M2 TAMs (as 
shown by the expression of macrophage scavenger receptor 1 
[MSR1], a marker of this cell type). However, we observed 
that the mean number of macrophages recruited to the tumor 
was lower in Sema4D KO than in WT mice (19.03   ±   5.2 and 
35.57   ±   4.2 F4/80  +   cells/fi  eld, respectively). 
  To prove the role of TAM-produced Sema4D in tumor 
angiogenesis and growth, we performed several experiments. 
To begin, we purifi  ed and cultured TAMs from tumors grown 
both in WT and KO mice (  37  ). Although the supernatant of 
cultures of WT TAMs was able to effi   ciently promote EC 
migration, the supernatant of KO TAMs was signifi  cantly less 
eff  ective; moreover, the chemoattractive activity of WT su-
pernatant was partially lost in the presence of Sema4D or 
plexin B1 blocking antibodies (  Fig. 4 E  ) (  16, 38  ). 
  Because we have previously shown that recruitment of 
the c-Met tyrosine kinase receptor by the activated Sema4D 
receptor (plexin B1) is required for the angiogenic ability of 
Sema4D, we wondered if c-Met inhibition impaired TAM-
induced EC motility. In line with our previous results, inhi-
bition of c-Met with the small molecule PHA-665752 (  39  ) 
resulted in a signifi  cant decrease of EC motility in response to 
WT TAM supernatant (  Fig. 4 E  ). 
  To evaluate the in vivo angiogenic role of TAMs, Matri-
gel plugs containing either WT or KO TAMs were subcuta-
neously implanted in KO mice. After 14 d, mice received 
dextran-FITC and were killed. As shown in   Fig. 5 A  , Matrigel 
plugs containing known angiogenic factors (such as hepato-
cyte growth factor [HGF] or basic fi  broblast growth factor [b-
FGF]) displayed several well-organized vessels, plugs containing 
WT TAMs were also well vascularized and showed well-
formed and branched vessels, and plugs containing KO TAMs 
displayed small and poorly organized vessels.   Addition of 
blocking plexin B1 antibodies (ec6.9), as well as of the c-Met 
inhibitor PHA-665752, resulted in the lack of an organized 
vessel tree, suggesting that activation of these two receptors is 
mandatory for the Sema4D-induced angiogenic response. 
  Sema4D produced by TAMs increases the tumorigenic ability 
of cancer cells 
  To fi  nally prove that the ability of TAMs to produce Sema4D 
contributes to the tumorigenic ability of cancer cells, we 
coinjected TSA tumor cells and TAMs obtained either from 
WT or KO animals in KO mice. Coinjection of TSA cells 
and WT TAMs resulted in the formation of signifi  cantly 
larger tumor masses in comparison to those originated by TSA 
plus KO TAMs (  Fig. 5 B  ). We found a comparable number 
of TAMs (F4/80  +   cells) in the tumors of both groups of ani-
mals; moreover, we could detect positivity for Sema4D only 
in KO mice injected with WT TAMs (unpublished data). As 
expected, in the presence of WT or KO TAMs, tumor growth 
was enhanced in comparison to tumor cells alone, in agree-
ment with the previously described protumorigenic role of 
these cells (  35  ). 
    DISCUSSION   
  Tumor development is a complex event that involves not 
only tumor cells but also the surrounding stroma. In recent 
years, in fact, data collected both from experimental systems 
and clinical observations have strengthened the idea that the 
tumor microenvironment and neoplastic cells act in concert 
and contribute as a functional whole to the growth and pro-
gression of the tumor mass (  33  ). This idea was originally pro-
posed by Paget  ’  s famous   “  seed and soil  ”   hypothesis, which 
highlighted the possible contribution of stromal cells to the 
process of tumorigenesis (  33  ). 
  The mechanisms promoting tumor angiogenesis are not 
yet fully understood, but it is believed that the most important 
factor is tumor hypoxia, which induces the release of angio-
genic molecules from tumor cells, attracting ECs and infl  am-
matory cells. Recruited ECs migrate toward the hypoxic areas, 
whereas infl  ammatory cells, in turn, secrete molecules that in-
tensify the angiogenic stimulus. Once ECs are engaged, peri-
vascular support cells stabilize nascent vessels and guarantee 
appropriate blood fl  ow (  28  ). Many molecules involved in these 
processes have been identifi  ed, and it has recently become clear 
that most of them originate from stromal cells recruited to the 
tumor microenvironment (  30  ). Tumor-infi  ltrating infl  ammatory 
cells undergo a process of maturation or   “  education  ”   within 
the tumor microenvironment (  40  ), and pharmacological or 
genetic inhibition of molecules that are up-regulated in these 
cells was indeed shown to be able to impair tumor progression 
in animal models (  33  ). 
  In this scenario, a critical role has been demonstrated for 
TAMs that represent the major infl  ammatory component of 
the stroma of many tumors (  41  ). Experimental models have 
demonstrated that the lack of recruitment of macrophages at 
the tumor site results in decreased tumorigenic ability (  42  ), 
and clinical evidence has shown that there is a correlation 
between a high TAM content inside the tumor and a poor 
prognosis (  41  ). These results have been recently confi  rmed 1680 STROMAL S  EMA  4D CONTRIBUTES TO TUMOR ANGIOGENESIS AND METASTASIS   | Sierra et al. 
tumor angiogenesis is partially diff  erent from the norm (in 
fact, tumor vessels are often abnormal in structure and func-
tion) and is characterized by an altered vessel maturation, pos-
sibly because of an inappropriate balance between vasculogenic 
and angiogenic factors (  44  ). We thus wondered if Sema4D 
could play any role in tumor angiogenesis. In this paper, we 
show that Sema4D is required for proper vessel maturation in 
tumors, as its defi  ciency results in the presence of vessels of 
smaller diameter that are poorly lined by perimural cells, such 
by gene profi  ling data showing that genes associated to leu-
kocyte or macrophage infi  ltration are part of the molecular 
signatures linked to a poor prognosis in breast cancer (  43  ). 
In this line, the identifi  cation of macrophage-derived mole-
cules that support the protumoral activity of these cells be-
comes very important. 
  Sema4D is a proangiogenic factor (  13  –  17  ), but this activ-
ity is dispensable for   “  normal  ”   angiogenesis because Sema4D 
KO mice are viable (  19  ). It has been previously shown that 
    Figure 5.         Sema4D produced by TAMs promotes angiogenesis and increases the tumorigenic ability of cancer cells.   (A) Matrigel plugs contain-
ing either WT or KO TAMs were subcutaneously implanted in KO mice. After 14 d, mice received dextran-FITC and were killed, and plugs were microscopi-
cally analyzed. As shown, plugs containing WT TAMs were well vascularized and showed well-formed and branched vessels, whereas plugs containing KO 
TAMs displayed small and poorly organized vessels. Addition of blocking plexin B1 antibodies, as well as of the c-Met inhibitor PHA-665752, resulted in 
the lack of an organized vessel tree. Plugs containing PBS were used as a negative control, whereas plugs containing known angiogenic factors (HGF and 
b-FGF) were used as positive controls. (  n   = 3 plugs per group). Bar, 2 mm. (B) TSA tumor cells were injected in KO mice alone or together with TAMs ob-
tained either from WT or KO animals. TSA cells alone were also injected in WT mice as a control. Coinjection of TSA cells and WT TAMs resulted in the 
formation of signifi  cantly larger tumor masses in comparison to those originated by TSA plus KO TAMs. Bars represent the mean   ±   SEM.     JEM VOL. 205, July 7, 2008 
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  We show that Sema4D exerts its activity on ECs through 
its high affi   nity receptor plexin B1, as demonstrated by the 
lack of chemotactic and angiogenic responses in the presence 
of plexin B1 blocking antibodies. Moreover, as previously 
reported (  8, 13  ), plexin-induced c-Met activation is a crucial 
event in Sema4D signal transduction, as c-Met inhibition re-
sulted in the loss of Sema4D-induced biological responses. 
  On the basis of the reported results and of data derived 
from the literature, how can we fi  gure the activity of Sema4D 
in the tumor stroma? We propose the following model. Can-
cer cells start to grow and reach a mass that becomes hypoxic. 
Hypoxia induces several changes in cancer cells and is a strong 
recruiting factor for TAMs. TAMs, indeed, accumulate pref-
erentially in poorly vascularized tumor regions, where they 
stop and   “  adapt  ”   to hypoxia by increasing the expression of 
hypoxia-inducible and proangiogenic genes (  46, 47  ). Most of 
these activities are mediated by the hypoxia-responsive tran-
scription of hypoxia-inducible factor 1; its inhibition, in fact, 
resulted in in vivo impairment of macrophage motility and 
activation (  48  ). Among the genes induced by hypoxia are the 
  c-Met   tyrosine kinase (  49  ) and   Sema4D   (  17  ). TAM-derived 
Sema4D can thus trigger the plexin expressed by macrophages 
and activate c-Met. This receptor, in turn, promotes the pro-
duction of several cytokines that can contribute to the protu-
morigenic activity of these cells (  50  ). Among the several proteases 
produced by TAMs is membrane type 1 metalloproteinase 
(whose expression is also induced by hypoxia) (  51  ), which can 
cleave the membrane-bound Sema4D and induce its release as 
a soluble protein (  17  ) able to act on distant cells. Production 
of the soluble form has been shown to be critical for the an-
giogenic activity of Sema4D (  17  ), as it can diff  use and act on 
ECs, stimulating angiogenesis, and on mural cells, promoting 
their recruitment. Secreted Sema4D can also stimulate the in-
vasive ability of cancer cells (which very frequently express its 
receptor). In previous works, we have shown that this biolog-
ical activity requires the recruitment of c-Met, probably facili-
tated by hypoxia-induced c-Met overexpression (  8, 13, 49  ). 
Loss of c-Met activation can be one of the mechanisms con-
tributing to the decreased metastatic ability of cancer cells grown 
in KO mice. 
  In conclusion, we have identifi  ed a novel molecule pro-
duced in the tumor stroma that can contribute to the interac-
tion between the tumor microenvironment and tumor cells by 
promoting tumor angiogenesis and invasion. This molecule is 
produced by macrophages, a cell type that is strongly impli-
cated in tumor progression and associated with a poor progno-
sis of several tumor types. As many attempts are now ongoing 
to target the tumor stroma, we propose Sema4D as a new can-
didate for antiangiogenic and antimetastatic cancer therapy. 
  MATERIALS AND METHODS 
  Cell culture 
  TSA, 66cl4, 168FARN, MLP29, and 4T1 cells were cultured in DMEM and 
were supplemented with 10% FBS, 100 U/ml penicillin, and 100   μ  g/ml 
streptomycin. Human umbilical vein endothelial cells (HUVECs) were cul-
tured on 1% gelatin  –  coated dishes in endothelial cell basal medium-2 (Lonza) 
and were used at early passages (II  –  V). 
as pericytes. Interestingly, we have observed that the number 
of lymphatic vessels in the tumors is not altered in Sema4D 
KO mice (unpublished data). We also demonstrate that the 
angiogenic Sema4D is produced by stromal cells infi  ltrating 
the tumor. Although another paper has shown an angiogenic 
role of tumor-derived Sema4D (  16  ), we could not observe a 
diff  erent behavior of breast cancer cells, either producing 
Sema4D (TSA, 4T1, and 168FARN; unpublished data) or not 
(66cl4; reference   45  ), when they where subcutaneously in-
jected in KO mice. Moreover, when we silenced the expres-
sion of this semaphorin in the producing cells, we did not 
observe any signifi  cant diff  erence compared with control cells 
(Fig. S6, available at http://www.jem.org/cgi/content/full/
jem.20072602/DC1). A possible reason for these divergences 
can be caused by the diff  erent tumor types used in the two 
experimental systems. In breast cancer, in fact, a very good 
correlation has been established between the presence of a 
strong infl  ammatory component, mainly containing TAMs, 
and the malignant behavior (  35, 43  ). It is possible that the 
head and neck carcinoma cells used by Basile et al. (  16  ) rely 
on diff  erent mechanisms to promote angiogenesis and are less 
dependent on the tumor microenvironment. 
  The tumor stroma contains several cell types, either   “  resi-
dent  ”   (such as fi  broblasts or adipocytes) or   “  infi  ltrated.  ”   Be-
cause most of the Sema4D  +   cells were also positive for leukocyte 
markers, we hypothesized that they were blood-derived cells. 
Bone marrow transplantation experiments formally proved 
that the Sema4D-producing cells are indeed of hematopoietic 
origin, as we could recover the WT phenotype (concerning 
tumor growth and angiogenesis) by transplanting a WT bone 
marrow into Sema4D KO mice. 
  A recent report has highlighted the role of Sema4D in 
platelet activation and thrombus formation (  21  ). Because it 
is known that blood clotting contributes to tumor growth 
and dissemination by creating a fi  brin clot surrounding tu-
mor cells that can protect them from apoptosis (  31  ), we in-
vestigated whether platelet-derived Sema4D could contribute 
to tumor growth. Chronic treatment of mice with clopido-
grel and aspirin did not result in signifi  cant changes in the 
growth of grafted tumors either in WT or KO mice. These 
results suggest that platelet-derived Sema4D is not required 
for tumor angiogenesis. 
  Among the cells of the tumor stroma, we found the highest 
levels of Sema4D in TAMs, expressing markers of the M2 type. 
These cells are known to tune infl  ammatory responses and adap-
tive Th2 immunity, to scavenge debris, and to promote angio-
genesis, tissue remodeling, and repair (  35  ). We found that 
M2-type TAMs were also present in the microenvironment of 
Sema4D KO mice and that the absence of this molecule did not 
signifi  cantly aff  ect their functional response to activating stimuli 
and their ability to produce cytokines. However, the inability of 
TAMs to produce Sema4D strongly decreased their capacity to 
attract ECs, in vitro and in vivo  ,   and to promote vessel matura-
tion. Moreover, WT-derived TAMs coinjected with tumor 
cells in KO animals were able to promote tumor growth at 
similar levels as in WT mice. 1682 STROMAL S  EMA  4D CONTRIBUTES TO TUMOR ANGIOGENESIS AND METASTASIS   | Sierra et al. 
in TBS  –  0.1% Tween 20. Secondary antibodies were purchased from Invitro-
gen. Pictures were taken with a DM IRB microscope connected to a DC350FX 
camera and analyzed with Metamorph 6.3 software. 
  Transwell assay 
  5   ×   10  4   TSA, 66cl4, and 4T1 cells or 3   ×   10  4   HUVECs were seeded on the 
upper surface of 8-  μ  m porous Transwell fi  lters (Corning), coated on both sides 
with 3,000 ng/ml fi  bronectin. Upper chambers were fi  lled with RPMI 1640 
with 2% FBS, whereas lower chambers were supplied with RPMI 1640 with 
2% FBS plus 6 nM Sema4D or 4 nM HGF (R  &  D Systems). For EC migra-
tion, RPMI 1640 with 2% FBS was placed in upper chambers, whereas TAM 
supernatants (WT or Sema4D KO) were placed in the lower chamber. Inhibi-
tory molecules were added into the lower chamber compartment as follows: 
100 ng/ml anti  –  plexin B1 (EC6.9; reference   52  ), 100 ng/ml anti-Sema4D 
(clone BMA-12; reference   19  ), 100 ng/ml anti  –  vesicular stomatitis virus 
(VSV; Sigma-Aldrich), and 100 nM PHA-665752 (Tocris Bioscience). As 
positive controls 6 nM Sema4D or 4 nM HGF (R  &  D Systems) were used. 
After 12 h of incubation, cells on the upper surface of the membrane were 
mechanically removed; cells that migrated to the lower face were fi  xed in 11% 
glutaraldehyde for 10 min and then stained with crystal violet for 5 min. 
Stained cells were quantifi  ed by counting. 
  Bone marrow transplantation 
  In one set of experiments, two tail-vein injections (with an interval of 
1 h) of 8   ×   10  7   male WT bone marrow cells were delivered into female 
Sema4D KO mice. In another set, lethally irradiated (900 cGy) female 
WT mice were injected with 5   ×   10  6   male Sema4D KO or WT bone 
marrow cells. 2 wk after transplantation, genomic DNA was extracted 
(QIAGEN) from peripheral blood monocytes obtained from tail vein 
puncture. Genomic DNA was quantifi  ed and PCR amplifi  ed with ZFY1- 
and     -actin  –  specifi  c primers: ZFY1 forward, 5    -CAATCCCAAACCT-
GCTTGT-3    ; ZFY1 reverse, 5    -CTCCCCTTCAGCTCTTCCTT-3    ; 
b-act forward, 5    -GCTTACACTGCGCTTCTTGC-3    ; and b-act re-
verse, 5    -AGAAAGGGCCACAGGAAGTC-3    . As a positive control, we 
used genomic DNA obtained from males; as a negative control, we used 
genomic DNA obtained from females. To quantify the engraftment, we 
compared the PCR products obtained from the genomic DNA of periph-
eral leukocytes of transplanted mice with the products of PCR reactions 
performed on a standard titration curve of a DNA mix containing diff  erent 
ratios of male/female genomic DNA. 
  TAM purifi  cation 
  TAM purifi  cation was performed as previously described (  37  ). In brief, tu-
mors grown in either WT or Sema4D KO mice were surgically removed, 
minced, and left to disaggregate in 0.125% trypsin in PBS with constant stir-
ring at 37  °  C for 45 min. Trypsin was inactivated with FBS. Cells were later 
centrifuged and washed at 1,500 and 1,000 rpm with PBS. Cells were later 
left to adhere in serum-free RMPI 1640 for 1 h. Nonadherent cells were 
washed away. The remaining adherent cells were 90  –  95% F4/80  +  . For su-
pernatant collection, cells remained in serum-free conditions for 16 h and 
media were later collected. 
  Functional screening of peritoneal macrophages and TAMs 
  Peritoneal macrophages from WT or Sema4D KO mice were isolated and 
plated in DMEM containing 10% FBS. After 1 h of adherence, cells were 
washed twice in PBS. 100 ng/ml LPS was administered to macrophages. Total 
mRNA was extracted using the TRI  zol   extraction kit. 1   μ  g RNA was ret-
rotranscribed using M-MLV reverse transcriptase minus H in a fi  nal volume 
of 40   μ  l using the manufacturer  ’  s protocol. Amplifi  cation of 1   μ  l cDNA was 
performed using the following primers: mTNFa forward, 5    -TAGCCAG-
GAGGGAGAACAGA-3    ; mTNFa reverse, 5    -TTTTCTGGAGGGAGA-
TGTGG-3    ; bactin forward, 5    -TGTTACCAACTGGGACGACA-3    ; and 
bactin reverse, 5    -GGGGTGTTGAAGGTCTCAAA-3    . 
  TAMs were purifi  ed from tumors as described, and mRNA, obtained as 
described, was retrotranscribed and amplifi  ed by PCR with the following 
  In vivo tumorigenesis assay 
  All animal procedures were approved by the Ethical Commission of the Uni-
versity of Turin and by the Italian Ministry of Health. 5  –  8-wk-old Sema4D-
defi  cient  (  19  ) and WT BALB/c mice (Charles River Laboratories) were 
injected with 5   ×   10  5   TSA, 66cl4, or 168FARN cells and 10   ×   10  4   4T1 cells 
subcutaneously in both posterior fl   anks. Tumor appearance was evaluated 
every 2 d using a caliper. Tumor volume was calculated using the formula 
V = 4/3       ×   (d/2)  2     ×   (D/2), where d is the minor tumor axis and D is the 
major tumor axis. 
  Platelet inactivation.     Clopidogrel treatment was administrated in the 
drinking water at a concentration of 0.26 mg/ml (equivalent to an oral 
dosage of     30 mg/kg/day) (  32  ). Aspirin was administered in the drinking 
water at a concentration of 0.3 mg/ml (equivalent to an oral dosage of 
    30 mg/kg/day). Evaluation of platelet inactivation was performed by 
checking negativity of CD62p (BD Biosciences) by FACS. 
  Coinjection of TAMs.     2   ×   10  5   TSA cells and 10  5   TAMs, WT or KO 
derived, were coinjected subcutaneously in the posterior fl  anks of Sema4D 
KO mice. 
  Lung metastases analyses.     When tumors reached a volume of     800 mm  3  , 
animals were killed. We did not kill all of the mice at the same time; we al-
lowed some tumors of KO mice to grow longer, to reach a size comparable 
with that observed in WT mice when they were killed. Lungs were contrasted 
with black India ink to facilitate scoring of superfi  cial macrometastases. The 
analysis of micrometastases was performed on paraffi   n-embedded  sections 
stained with hematoxylin and eosin. 
  Vessel counting.     10 random fi  elds of eight representative tumor sections 
stained with anti-CD31 antibodies were analyzed as follows: vessels were 
counted manually using digital images taken with a microscope (DM IRB; 
Leica) connected to a camera (DC350FX; Leica) and analyzed with Meta-
morph 6.3 software (MDS Analytical Technologies). Vessel area is the total 
area occupied by vessels, whereas mean vessel size is vessel area/vessel number 
(as determined by averaging pixels contained inside of each vessel divided by 
the mean number of vessels). Structures without lumen at the magnifi  cation 
show in the fi  gures were examined at higher magnifi  cation, and only struc-
tures with a lumen at higher enlargement were counted. 
  Analysis of in vivo  –  activated macrophages 
  On day 0, WT mice received a single i.p. injection of 0.1 ml CFA (Sigma-
Aldrich) or 0.1 ml PBS. 3 d later, mice were killed. Peritoneal cells from 
control or treated mice were harvested by washing the peritoneal cavity with 
RPMI 1640 medium with 10% FBS. Cells were centrifuged at 1,200 rpm and 
washed twice with PBS. Cells were resuspended in RPMI 1640 serum-free 
medium and left to adhere for 1 h; nonadherent cells were removed by 
washing with PBS. Total RNA was extracted using a TRI  zol   extraction kit 
(Invitrogen). 1   μ  g RNA was retrotranscribed using M-MLV reverse transcrip-
tase minus H (Promega) in a fi  nal volume of 40   μ  l, according to the manufac-
turer  ’  s protocol. cDNA was later amplifi  ed by PCR using primers specifi  c for 
each mouse cytokine. 
  Immunofl  uorescence 
  Immunofl  uorescent analyses were performed according to standard techniques. 
In brief, tumors were embedded on optimum cutting temperature  –  cryostat 
embedding compound. 4-  μ  m sections were air dried and fi  xed in cold acetone. 
Sections were blocked for 2 h with blocking solution (2% goat serum, 1% BSA, 
0.1% cold fi  sh skin gelatin, 0.1% Triton X-100, 0.05% Tween 20, and 0.1 M 
PBS, pH 7.2). Primary antibodies were diluted 1:200 in antibody dilution solu-
tion containing 1% BSA, 0.1% cold fi  sh skin gelatin, and 0.1 M PBS, pH 7.2, 
for 1 h. Anti-CD31, anti-CD45, and anti-Sema4D were purchased from BD 
Biosciences. Anti-F4/80 was purchased from AbD Serotec. Anti-NG2 was 
purchased from Chemicon. Sections were washed with TBS  –  0.1% Tween 20 
and incubated for 30 min with secondary conjugated antibodies diluted 1:300 JEM VOL. 205, July 7, 2008 
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dextran-FITC (Sigma-Aldrich). Plugs were collected, immediately fi  xed in 
formalin, and analyzed using a fl  uorescent microscope. 
  Sema4D silencing 
  TSA cells were transduced with MISSION shRNA lentiviral plasmid pLKO.1-
puro (clone no. TRCN0000067495; Sigma-Aldrich) targeting the follow-
ing sequence: 5    -CCACAGCTACACATCAGTCAT-3    . Cells were selected 
using 2   μ  g/ml puromycin. 
  Statistical analyses 
  For analyses of experimental data, comparisons of data were performed us-
ing the Student  ’  s   t   test. All p-values are two tailed. P   <   0.001 was consid-
ered signifi  cant. 
  Online supplemental material 
  Fig. S1 shows that diff  erent syngeneic breast cancer cell lines grafted into 
Sema4D KO mice give rise to smaller tumors when compared with those 
observed in WT mice. Fig. S2 provides information regarding the ex-
pression of plexin B1 (high affi   nity receptor for Sema4D) in TSA cells; it 
also shows that Sema4D is able to promote the motogenic/invasive ability 
of the examined breast cancer cells. Fig. S3 illustrates that Sema4D produced 
by platelets does not contribute to tumor growth. Fig. S4 shows that hu-
man macrophages, but not monocytes, express Sema4D; it also shows that 
Sema4D expression is probably linked to macrophage activation better than 
diff  erentiation. Fig. S5 confi  rms that macrophages obtained from Sema4D 
KO mice are functionally similar to those taken from WT mice. Fig. S6 
shows that Sema4D silencing in mammary tumor cells does not aff  ect tumor 
growth. Online supplemental material is available at http://www.jem.org/
cgi/content/full/jem.20072602/DC1. 
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  Analysis of human monocytes 
  PMBCs were obtained and stained as previously described (  50, 53  ). In brief, 
PMBCs were obtained from healthy blood donors by Ficoll density gradient 
centrifugation. Mononuclear cells were washed three times in PBS, and 
25   ×   10  6   cells were plated on 10-cm diameter Petri dishes. Nonadherent cells 
were removed after a 1-h incubation and examined (sample labeled as day 0). 
A portion of the PMBCs was kept in culture for 48 h in the absence of dif-
ferentiating factors (sample labeled as day 2). Surface staining of cells was 
performed using the following antibodies: anti-Sema4D (Beckman Coulter) 
and anti-CD14 (monocyte-specifi   c marker; Invitrogen). Isotype controls 
were performed in each experiment. 
  To evaluate the response of monocytes to diff  erent stimuli, PBMCs were 
purifi  ed by magnetic beads and stimulated for 24 h in the presence of one of 
the following molecules: 100 ng/ml IL-10, 100 ng/ml TGF-    , 100 ng/ml 
M-CSF (PrepoTech), 100 mg/ml LPS, or 100 nM PMA (Sigma-Aldrich). 
Hypoxia was induced by incubating cells in a 3% O  2   atmosphere. After 24 h, 
cells were washed with PBS and total mRNA was extracted using the 
TRI  zol   extraction kit. 1   μ  g RNA was retrotranscribed using M-MLV 
reverse transcriptase minus H in a fi  nal volume of 40   μ  l, according to 
manufacturer  ’  s protocol. cDNA was amplifi  ed using the following primers: 
hSema4D forward, 5    -CCAGCTCTTCCAGGACTTTG-3    ; hSema4D re-
verse, 5    -ACTTTTATCCGGGCACACAG-3    ; hTNFa forward, 5    -C  C  A-
A  G  C  CCTGGTATGAGC-3    ; hTNFa reverse, 5    -GGGCAATG  A  T  C  C-
C  A  AAGTAG-3    ; hIL-10 forward, 5    -GTTGCCAAGCCTTGTCTGA-3    ; 
hIL-10 reverse, 5    -GGCCTTGCTCTTGTTTTCAC-3    ; hGAPDH for-
ward, 5    -ACAGTCAGCCGCATCTTCTT-3    ; and hGAPDH reverse, 
5    -GACAAGCTTCCCGTTCTCAG-3    . 
  Immunoblot analysis 
  WT or Sema4D TAMs were lysed with Laemmli buff  er (67.5 mM Tris, 2% 
SDS), and 100   μ  g of proteins was run on 8% SDS-PAGE. TSA and MLP29 
cells were lysed in EB buff  er, as previously described (  8  ). 500   μ  g of protein 
was immunoprecipitated with 2   μ  g anti  –  plexin B1 and 2   μ  g of rabbit anti  –
  mouse Ig for 3 h in a rotating wheel at 4  °  C. 100   μ  g of protein and immuno-
precipitations were subjected to 8% SDS-PAGE. Anti-Sema4D antibody 
was purchased from BD Biosciences; anti  –      -actin (I-19) and anti  –  plexin B1 
(A-8) were purchased from Santa Cruz Biotechnology, Inc. 
  Matrigel plugs 
  500   μ  l of Matrigel (Becton Dickinson) was injected subcutaneously in the 
ventral area of Sema4D KO mice. Matrigel plugs contained 2   ×   10  5   TAMs 
(WT or Sema4D derived) in the presence or absence of 100 ng/ml anti  –  plexin 
B1 (ec6.9), anti-VSV antibodies, or 100 nM PHA-665752. Control plugs 
contained 36 ng/ml HGF (R  &  D Systems), 200 ng/ml b-FGF (R  &  D Sys-
tems), or an equivalent amount of PBS (negative control). Each experimen-
tal condition was analyzed in triplicate. 14 d after plug implantation, 5 min 
before death, mice received a 200-  μ  l tail-vein injection containing 20 mg/ml 1684 STROMAL S  EMA  4D CONTRIBUTES TO TUMOR ANGIOGENESIS AND METASTASIS   | Sierra et al. 
A is a neuronal semaphorin receptor that controls axon guidance.       Cell      .   
  95  :  903    –    916  .    
        25  .   Trusolino  ,   L.  , and   P.M.     Comoglio  .   2002  .   Scatter-factor and sema-
phorin receptors: cell signalling for invasive growth.       Nat. Rev. Cancer      .   
  2  :  289    –    300  .    
        26  .   Torisu  ,   H.  ,   M.     Ono  ,   H.     Kiryu  ,   M.     Furue  ,   Y.     Ohmoto  ,   J.     Nakayama  , 
  Y.     Nishioka  ,   S.     Sone  , and   M.     Kuwano  .   2000  .   Macrophage infi  ltration 
correlates with tumor stage and angiogenesis in human malignant mela-
noma: possible involvement of TNFalpha and IL-1alpha.       Int. J. Cancer      .   
  85  :  182    –    188  .   
        27  .   Welm  ,   A.L.  ,   J.B.     Sneddon  ,   C.     Taylor  ,   D.S.     Nuyten  ,   M.J.     van de Vijver  , 
  B.H.     Hasegawa  , and   J.M.     Bishop  .   2007  .   The macrophage-stimulating 
protein pathway promotes metastasis in a mouse model for breast can-
cer and predicts poor prognosis in humans.       Proc. Natl. Acad. Sci. USA      .   
  104  :  7570    –    7575  .    
        28  .   von Tell  ,   D.  ,   A.     Armulik  , and   C.     Betsholtz  .   2006  .   Pericytes and vascular 
stability.       Exp. Cell Res.       312  :  623    –    629  .    
        29  .   Yamagishi  ,   S.  , and   T.     Imaizumi  .   2005  .   Pericyte biology and diseases.   
    Int. J. Tissue React.       27  :  125    –    135  .   
        30  .   Ganss  ,   R.     2006  .   Tumor stroma fosters neovascularization by recruitment 
of progenitor cells into the tumor bed.       J. Cell. Mol. Med.       10  :  857    –    865  .    
        31  .   Boccaccio  ,   C.  ,   G.     Sabatino  ,   E.     Medico  ,   F.     Girolami  ,   A.     Follenzi  ,   G.   
  Reato  ,   A.     Sottile  ,   L.     Naldini  , and   P.M.     Comoglio  .   2005  .   The MET 
oncogene drives a genetic programme linking cancer to haemostasis.   
    Nature      .     434  :  396    –    400  .    
        32  .   Chiodoni  ,   C.  ,   M.     Iezzi  ,   C.     Guiducci  ,   S.     Sangaletti  ,   I.     Alessandrini  ,   C.   
  Ratti  ,   F.     Tiboni  ,   P.     Musiani  ,   D.N.     Granger  , and   M.P.     Colombo  .   2006  . 
  Triggering CD40 on endothelial cells contributes to tumor growth.    
  J. Exp. Med.       203  :  2441    –    2450  .    
        33  .   Albini  ,   A.  , and   M.B.     Sporn  .   2007  .   The tumour microenvironment as a 
target for chemoprevention.       Nat. Rev. Cancer      .     7  :  139    –    147  .    
        34  .   Zalatnai  ,   A.     2006  .   Molecular aspects of stromal-parenchymal inter-
actions in malignant neoplasms.       Curr. Mol. Med.       6  :  685    –    693  .    
        35  .   Mantovani  ,   A.  ,   T.     Schioppa  ,   C.     Porta  ,   P.     Allavena  , and   A.     Sica  .   2006  . 
  Role of tumor-associated macrophages in tumor progression and inva-
sion.       Cancer Metastasis Rev.       25  :  315    –    322  .    
        36  .   Lewis  ,   C.E.  , and   J.W.     Pollard  .   2006  .   Distinct role of macrophages in 
diff  erent tumor microenvironments.       Cancer Res.       66  :  605    –    612  .    
        37  .   Sica  ,   A.  ,   A.     Saccani  ,   B.     Bottazzi  ,   N.     Polentarutti  ,   A.     Vecchi  ,   D.J.     Van  , 
and   A.     Mantovani  .   2000  .   Autocrine production of IL-10 mediates de-
fective IL-12 production and NF-kappa B activation in tumor-associ-
ated macrophages.       J. Immunol.       164  :  762    –    767  .   
        38  .   Barberis  ,   D.  ,   S.     Artigiani  ,   A.     Casazza  ,   S.     Corso  ,   S.     Giordano  ,   C.A.     Love  , 
  E.Y.     Jones  ,   P.M.     Comoglio  , and   L.     Tamagnone  .   2004  .   Plexin signaling 
hampers integrin-based adhesion, leading to Rho-kinase independent 
cell rounding, and inhibiting lamellipodia extension and cell motility.   
    FASEB J.       18  :  592    –    594  .   
        39  .   Christensen  ,   J.G.  ,   R.     Schreck  ,   J.     Burrows  ,   P.     Kuruganti  ,   E.     Chan  ,   P.   
  Le  ,   J.     Chen  ,   X.     Wang  ,   L.     Ruslim  ,   R.     Blake  ,   et al  .   2003  .   A selective 
small molecule inhibitor of c-Met kinase inhibits c-Met-dependent 
phenotypes in vitro and exhibits cytoreductive antitumor activity in 
vivo.       Cancer Res.       63  :  7345    –    7355  .   
        40  .   Pollard  ,   J.W.     2001  .   Tumour-stromal interactions. Transforming growth 
factor-beta isoforms and hepatocyte growth factor/scatter factor in 
mammary gland ductal morphogenesis.       Breast Cancer Res.       3  :  230    –    237  .    
        41  .   Balkwill  ,   F.  , and   A.     Mantovani  .   2001  .   Infl  ammation and cancer: back to 
Virchow?       Lancet      .     357  :  539    –    545  .    
        42  .   Lin  ,   E.Y.  ,   J.F.     Li  ,   L.     Gnatovskiy  ,   Y.     Deng  ,   L.     Zhu  ,   D.A.     Grzesik  ,   H.   
  Qian  ,   X.N.     Xue  , and   J.W.     Pollard  .   2006  .   Macrophages regulate the 
angiogenic switch in a mouse model of breast cancer.       Cancer Res.     
  66  :  11238    –    11246  .    
        43  .   Paik  ,   S.  ,   S.     Shak  ,   G.     Tang  ,   C.     Kim  ,   J.     Baker  ,   M.     Cronin  ,   F.L.     Baehner  , 
  M.G.     Walker  ,   D.     Watson  ,   T.     Park  ,   et al  .   2004  .   A multigene assay to 
predict recurrence of tamoxifen-treated, node-negative breast cancer.   
    N. Engl. J. Med.       351  :  2817    –    2826  .    
        44  .   Carmeliet  ,   P.     2003  .   Angiogenesis in health and disease.       Nat. Med.     
  9  :  653    –    660  .    
        45  .   Fazzari  ,   P.  ,   J.     Penachioni  ,   S.     Gianola  ,   F.     Rossi  ,   B.J.     Eickholt  ,   F.     Maina  , 
  L.     Alexopoulou  ,   A.     Sottile  ,   P.M.     Comoglio  ,   R.A.     Flavell  , and   L.   
       6  .   Kumanogoh  ,   A.  , and   H.     Kikutani  .   2001  .   The CD100-CD72 inter-
action: a novel mechanism of immune regulation.       Trends Immunol.     
  22  :  670    –    676  .    
       7  .   Bismuth  ,   G.  , and   L.     Boumsell  .   2002  .   Controlling the immune system 
through semaphorins.       Sci. STKE      .     2002  :  RE4  .   
       8  .   Giordano  ,   S.  ,   S.     Corso  ,   P.     Conrotto  ,   S.     Artigiani  ,   G.     Gilestro  ,   D.   
  Barberis  ,   L.     Tamagnone  , and   P.M.     Comoglio  .   2002  .   The semaphorin 
4D receptor controls invasive growth by coupling with Met.       Nat. Cell 
Biol.       4  :  720    –    724  .    
       9  .   Tse  ,   C.  ,   R.H.     Xiang  ,   T.     Bracht  , and   S.L.     Naylor  .   2002  .   Human 
Semaphorin 3B (SEMA3B) located at chromosome 3p21.3 sup-
presses tumor formation in an adenocarcinoma cell line.       Cancer Res.     
  62  :  542    –    546  .   
        10  .   Christensen  ,   C.R.  ,   J.     Klingelhofer  ,   S.     Tarabykina  ,   E.F.     Hulgaard  ,   D.   
  Kramerov  , and   E.     Lukanidin  .   1998  .   Transcription of a novel mouse 
semaphorin gene, M-semaH, correlates with the metastatic ability of 
mouse tumor cell lines.       Cancer Res.       58  :  1238    –    1244  .   
        11  .   Carmeliet  ,   P.  , and   M.     Tessier-Lavigne  .   2005  .   Common mechanisms of 
nerve and blood vessel wiring.       Nature      .     436  :  193    –    200  .    
        12  .   Miao  ,   H.Q.  ,   S.     Soker  ,   L.     Feiner  ,   J.L.     Alonso  ,   J.A.     Raper  , and   M.   
  Klagsbrun  .   1999  .   Neuropilin-1 mediates collapsin-1/semaphorin III 
inhibition of endothelial cell motility: functional competition of col-
lapsin-1 and vascular endothelial growth factor-165.       J. Cell Biol.     
  146  :  233    –    242  .   
        13  .   Conrotto  ,   P.  ,   D.     Valdembri  ,   S.     Corso  ,   G.     Serini  ,   L.     Tamagnone  ,   P.M.   
  Comoglio  ,  F.    Bussolino  , and  S.    Giordano  .  2005  .  Sema4D induces angio-
genesis through Met recruitment by Plexin B1.       Blood      .     105  :  4321    –    4329  .     
        14  .   Basile  ,   J.R.  ,   T.     Afkhami  , and   J.S.     Gutkind  .   2005  .   Semaphorin 4D/
plexin-B1 induces endothelial cell migration through the activation of 
PYK2, Src, and the phosphatidylinositol 3-kinase-Akt pathway.       Mol. 
Cell. Biol.       25  :  6889    –    6898  .    
        15  .   Basile  ,   J.R.  ,   A.     Barac  ,   T.     Zhu  ,   K.L.     Guan  , and   J.S.     Gutkind  .   2004  . 
  Class IV semaphorins promote angiogenesis by stimulating Rho-initi-
ated pathways through plexin-B.       Cancer Res.       64  :  5212    –    5224  .    
        16  .   Basile  ,   J.R.  ,   R.M.     Castilho  ,   V.P.     Williams  , and   J.S.     Gutkind  .   2006  . 
  Semaphorin 4D provides a link between axon guidance processes and tu-
mor-induced angiogenesis.       Proc. Natl. Acad. Sci. USA      .     103  :  9017    –    9022  .     
        17  .   Basile  ,   J.R.  ,   K.     Holmbeck  ,   T.H.     Bugge  , and   J.S.     Gutkind  .   2007  .   MT1-
MMP controls tumor-induced angiogenesis through the release of 
semaphorin 4D.       J. Biol. Chem.       282  :  6899    –    6905  .    
        18  .   Hall  ,   K.T.  ,   L.     Boumsell  ,   J.L.     Schultze  ,   V.A.     Boussiotis  ,   D.M.     Dorfman  , 
  A.A.     Cardoso  ,   A.     Bensussan  ,   L.M.     Nadler  , and   G.J.     Freeman  .   1996  . 
  Human CD100, a novel leukocyte semaphorin that promotes B-
cell aggregation and diff  erentiation.       Proc. Natl. Acad. Sci. USA      .   
  93  :  11780    –    11785  .    
        19  .   Shi  ,   W.  ,   A.     Kumanogoh  ,   C.     Watanabe  ,   J.     Uchida  ,   X.     Wang  ,   T.     Yasui  , 
  K.     Yukawa  ,   M.     Ikawa  ,   M.     Okabe  ,   J.R.     Parnes  ,   et al  .   2000  .   The class 
IV semaphorin CD100 plays nonredundant roles in the immune system: 
defective B and T cell activation in CD100-defi  cient mice.       Immunity      .   
  13  :  633    –    642  .    
        20  .   Elhabazi  ,   A.  ,   S.     Delaire  ,   A.     Bensussan  ,   L.     Boumsell  , and   G.     Bismuth  . 
  2001  .   Biological activity of soluble CD100. I. The extracellular region 
of CD100 is released from the surface of T lymphocytes by regulated 
proteolysis.       J. Immunol.       166  :  4341    –    4347  .   
        21  .   Zhu  ,   L.  ,   W.     Bergmeier  ,   J.     Wu  ,   H.     Jiang  ,   T.J.     Stalker  ,   M.     Cieslak  ,   R.   
  Fan  ,   L.     Boumsell  ,   A.     Kumanogoh  ,   H.     Kikutani  ,   et al  .   2007  .   Regulated 
surface expression and shedding support a dual role for semaphorin 
4D in platelet responses to vascular injury.       Proc. Natl. Acad. Sci. USA      .   
  104  :  1621    –    1626  .    
        22  .   Masuda  ,   K.  ,   T.     Furuyama  ,   M.     Takahara  ,   S.     Fujioka  ,   H.     Kurinami  , and 
  S.     Inagaki  .   2004  .   Sema4D stimulates axonal outgrowth of embryonic 
DRG sensory neurones.       Genes Cells      .     9  :  821    –    829  .    
        23  .   Kumanogoh  ,   A.  ,   C.     Watanabe  ,   I.     Lee  ,   X.     Wang  ,   W.     Shi  ,   H.     Araki  , 
  H.     Hirata  ,   K.     Iwahori  ,   J.     Uchida  ,   T.     Yasui  ,   et al  .   2000  .   Identifi  cation 
of CD72 as a lymphocyte receptor for the class IV semaphorin 
CD100: a novel mechanism for regulating B cell signaling.       Immunity      .   
  13  :  621    –    631  .    
        24  .   Winberg  ,   M.L.  ,   J.N.     Noordermeer  ,   L.     Tamagnone  ,   P.M.     Comoglio  , 
  M.K.     Spriggs  ,   M.     Tessier-Lavigne  , and   C.S.     Goodman  .   1998  .   Plexin JEM VOL. 205, July 7, 2008 
ARTICLE
1685
  Tamagnone  .   2007  .   Plexin-B1 plays a redundant role during mouse 
development and in tumour angiogenesis.       BMC Dev. Biol.       7  :  55  .    
        46  .   Knowles  ,   H.  ,   R.     Leek  , and   A.L.     Harris  .   2004  .   Macrophage infi  ltra-
tion and angiogenesis in human malignancy.       Novartis Found. Symp.     
  256  :  189    –    200  .   
        47  .   Talks  ,   K.L.  ,   H.     Turley  ,   K.C.     Gatter  ,   P.H.     Maxwell  ,   C.W.     Pugh  ,   P.J.   
  Ratcliff  e  , and   A.L.     Harris  .   2000  .   The expression and distribution of the 
hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal hu-
man tissues, cancers, and tumor-associated macrophages.       Am. J. Pathol.     
  157  :  411    –    421  .   
        48  .   Cramer  ,   T.  ,   Y.     Yamanishi  ,   B.E.     Clausen  ,   I.     Forster  ,   R.     Pawlinski  ,   N.   
  Mackman  ,   V.H.     Haase  ,   R.     Jaenisch  ,   M.     Corr  ,   V.     Nizet  ,   et al  .   2003  . 
  HIF-1alpha is essential for myeloid cell-mediated infl  ammation.       Cell      .   
  112  :  645    –    657  .    
        49  .   Pennacchietti  ,   S.  ,   P.     Michieli  ,   M.     Galluzzo  ,   M.     Mazzone  ,   S.     Giordano  , 
and   P.M.     Comoglio  .   2003  .   Hypoxia promotes invasive growth by 
transcriptional activation of the met protooncogene.       Cancer Cell      .   
  3  :  347    –    361  .    
        50  .   Galimi  ,   F.  ,   E.     Cottone  ,   E.     Vigna  ,   N.     Arena  ,   C.     Boccaccio  ,   S.     Giordano  , 
  L.    Naldini  , and  P.M.    Comoglio  .  2001  .  Hepatocyte growth factor is a reg-
ulator of monocyte-macrophage function.       J. Immunol.       166  :  1241    –    1247  .   
        51  .   Ray  ,  B.K.  ,  A.    Shakya  ,  J.R.    Turk  ,  S.S.    Apte  , and  A.    Ray  .  2004  .  Induction 
of the MMP-14 gene in macrophages of the atherosclerotic plaque: role 
of SAF-1 in the induction process.       Circ. Res.       95  :  1082    –    1090  .    
        52  .   Barberis  ,  D.  ,   A.     Casazza  ,  R.     Sordella  ,  S.     Corso  ,   S.     Artigiani  ,   J.     Settleman  , 
  P.M.     Comoglio  , and   L.     Tamagnone  .   2005  .   p190 Rho-GTPase activat-
ing protein associates with plexins and it is required for semaphorin 
signalling.       J. Cell Sci.       118  :  4689    –    4700  .    
        53  .   Granziero  ,   L.  ,   P.     Circosta  ,   C.     Scielzo  ,   E.     Frisaldi  ,   S.     Stella  ,   M.     Geuna  ,   S.   
  Giordano  ,   P.     Ghia  , and   F.     Caligaris-Cappio  .   2003  .   CD100/Plexin-B1 
interactions sustain proliferation and survival of normal and leukemic 
CD5+ B lymphocytes.       Blood      .     101  :  1962    –    1969  .                  